Advertiser / Brand
AbbVie vs Medtronic
Structured technology and market comparison · 2026
Direct Feature Comparison
AbbVie · vs · MedtronicBiopharmaceutical company developing and commercialising prescription medicines.
Global medical device and healthcare technology manufacturer.
Analyze all overlapping signals and tech stacks for AbbVie and Medtronic
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between AbbVie and Medtronic?
AbbVie anchors its market position in advanced biopharmaceuticals, leveraging strong intellectual property to deliver breakthrough prescription therapeutics. Conversely, Medtronic specializes in medical technology and devices for clinical interventions. While AbbVie targets systemic disease management through molecular science, Medtronic serves institutional healthcare providers with hardware, diagnostics, and surgical infrastructure, differing significantly in regulatory and distribution dynamics.
How do the features of AbbVie and Medtronic compare?
AbbVie's portfolio features complex biologics and small-molecule drugs addressing immunology, oncology, and neuroscience. Medtronic offers physical medical devices spanning cardiac rhythms, surgical robotics, and patient monitoring. There is minimal direct product overlap; AbbVie suits pharmacotherapy procurement, whereas Medtronic serves hospital capital equipment and surgical supply budgets.
What are the top alternatives to AbbVie and Medtronic?
When evaluating AbbVie and Medtronic, enterprise buyers also consider other platforms in Advertiser / Brand. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of AbbVie and Medtronic compare?
AbbVie is headquartered in US (founded in 2012) with >5,000 employees. Medtronic is based in IE (founded in 1949) with >5,000 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: AbbVie vs Medtronic
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
AbbVie
Recent Signals
- ·AbbVie
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival...
- ·AbbVie
U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease
JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease. Taken once daily with or without levodopa therapy, JUVMO offers patients a...
- ·AbbVie
AbbVie Participates in USTR’s Section 301 Investigation into Germany to Address Global Imbalances in How Transformative Medicines are Valued
On behalf of AbbVie, Perry Siatis, Executive Vice President, General Counsel and Secretary, testified in front of the U.S. Trade Representative (USTR) on...
Medtronic
Recent Signals
- ·EU-Startups (European Venture)HealthTech
XRlabs Raises €7.48M for AI Surgical Intelligence
London-based XRlabs, a Surgical Intelligence company founded by neurosurgeon Dr. Ali Haddad, has raised €7.48 million ($8.4 million) in Seed funding. The round was led by Playground Global (Palo Alto), with participation from London-based HealthTech investor Eka Ventures. The company develops modular, device-agnostic software that uses computer vision and deep learning to transform live surgical video, navigation telemetry, and pre-operative imaging into a real-time, anatomy-aware view. Its platform has been deployed in over 100 surgical cases across three continents. The funding will support engineering and clinical team expansion, regulatory advancement in the UK, EU, and US, and the extension of clinical evidence. XRlabs also announced Omar Ishrak, former CEO of Medtronic, as Chair of its Board. The company has been awarded compute allocation on the UK AI Research Resource (AIRR).
- XRlabs raised €7.48 million ($8.4 million) in Seed funding led by Playground Global with participation from Eka Ventures.
- Omar Ishrak, former CEO of Medtronic, joined as Chair of XRlabs' Board of Directors.
- The company's platform has been deployed in over 100 surgical cases on three continents.
- ·SEC APIfinancials
8-K Financial Filing Analysis for Medtronic (2026-09-01)
On September 1, 2026, Medtronic plc filed a Form 8-K under Item 2.02 (Results of Operations and Financial Condition) announcing its financial results for the first quarter of fiscal year 2027. The details of the quarterly performance were furnished via press release in Exhibit 99.1, signed by Executive Vice President and Chief Financial Officer Thierry Piéton.
- Medtronic plc furnished its Q1 FY2027 financial results via Form 8-K on September 1, 2026.
- The earnings announcement is furnished under Item 2.02 with details provided in Exhibit 99.1.
- The filing was formally authorized and signed by Executive Vice President and CFO Thierry Piéton.
- ·Medtronic
Medtronic Announces Final Exchange Ratio of 4.5939 in Split-Off of MiniMed Group, Inc.
Medtronic plc (Medtronic; NYSE: MDT) today announced the final exchange ratio for its previously announced offer to exchange outstanding Medtronic ordinary shares for shares of common stock of MiniMed Group, Inc.
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners AbbVie and Medtronic share across the market ecosystem.
Unlock full capability matrix, client overlaps & technology stacks